Kevin was 45 with what his annual physical called a perfectly normal fasting blood glucose of 97 mg/dL. His doctor was happy. Kevin — who’d been reading about metabolic health obsessively for the past year — was not. He’d seen that the optimal range most functional medicine practitioners cite is 70-85 mg/dL. He was 12 points above optimal but 3 points below the prediabetes threshold. Where exactly did that leave him, and what did the number actually mean?
He was sitting in what’s sometimes called the metabolic gray zone — not sick enough for conventional medicine to flag, but not at optimal function either. His number was telling a story the standard reference range wasn’t designed to read. Here’s what fasting blood glucose actually measures, why the standard reference range misleads for preventive purposes, and what a given number actually means for long-term health trajectory.
Fasting blood glucose (FBG) is exactly what it sounds like: the concentration of glucose in the blood after an overnight fast, typically measured after 8-12 hours without caloric intake. It’s usually taken first thing in the morning, before breakfast, reported in milligrams per deciliter (mg/dL) in the US or millimoles per liter (mmol/L) elsewhere.
What it reflects is baseline glucose homeostasis — the equilibrium the metabolic system has settled at when it isn’t actively processing food. That baseline is determined by several interacting variables: the rate of hepatic glucose output (the liver releasing glucose into the bloodstream through glycogenolysis and gluconeogenesis), the rate of cellular glucose uptake (mostly muscle and brain), and the balance of hormones governing all of it — primarily insulin, glucagon, cortisol, and growth hormone.
In a metabolically healthy person, the liver releases glucose at a slow basal rate overnight to maintain brain function, and insulin — released in small basal pulses — keeps that output appropriately regulated. Fasting glucose stays in a tight range because the feedback system is working. In someone with developing insulin resistance, the liver becomes less responsive to insulin’s suppressive signal and releases more glucose than necessary, pushing fasting glucose upward even though nothing’s been eaten in ten hours. The elevated number isn’t caused by dinner. It’s caused by the liver misbehaving overnight.
This is why fasting glucose is a useful metabolic health marker: it isn’t measuring the response to a specific meal, it’s measuring the baseline regulation of glucose metabolism when it’s supposed to be running on autopilot. A number drifting upward over years means the autopilot is progressively losing precision. Kevin’s 97 mg/dL said something specific about his liver’s overnight insulin sensitivity.
The Reference Range Problem
The standard clinical reference range for fasting blood glucose is 70-99 mg/dL (“normal”), 100-125 mg/dL (“prediabetes” or impaired fasting glucose), and 126 mg/dL or above (type 2 diabetes on two separate readings). These thresholds exist mainly to identify people at high risk of progressing to clinical diabetes — calibrated as disease risk cutoffs, not optimal function benchmarks.
That distinction matters enormously for preventive health. The 70-99 mg/dL range spans 29 points. It includes someone at 72 mg/dL (excellent glucose regulation, low metabolic risk) and someone at 98 mg/dL (significantly impaired regulation relative to optimal, measurably elevated risk for cardiovascular disease, cognitive decline, eventual diabetes) in the exact same “normal” category. Like saying a 4-minute miler and someone who barely finishes a mile at all are both “normal runners.”
The epidemiological data on fasting glucose and mortality doesn’t support treating the 70-99 range as uniformly equivalent. A major study published in 2010 in the Journal of the American College of Cardiology by Levitan et al. followed 46,578 men and found a linear relationship between fasting glucose and cardiovascular mortality starting from values as low as 85 mg/dL — well within the “normal” clinical range. Compared to men with fasting glucose below 85 mg/dL, those at 95-99 mg/dL had 49% higher cardiovascular mortality. Those at 100-109 mg/dL — officially still prediabetes, not yet a concern for many doctors — had 2.4 times the cardiovascular mortality.
These aren’t subtle differences. A fasting glucose of 97 mg/dL — Kevin’s number, his doctor’s “normal” — is associated in the literature with meaningfully elevated cardiovascular risk compared to genuinely optimal values. It doesn’t mean Kevin is heading for a heart attack. It means his metabolic system is running suboptimally in ways that, left unchanged, compound over the next two decades into clinically significant outcomes.
The Optimal Range: Why 70-85 mg/dL
Functional and preventive medicine practitioners have increasingly settled on 70-85 mg/dL as the optimal fasting glucose range, based on epidemiological data showing minimal disease risk across that range and biological research indicating it reflects genuinely tight glucose regulation rather than the looser regulation that shows up in the 90s.
A landmark study by Coutinho et al., published in 1999 in Diabetes Care — a meta-analysis of 20 studies covering 95,783 individuals — found a graded, continuous relationship between fasting glucose and cardiovascular risk starting from 75 mg/dL. Non-linear: each unit increase produced a larger risk increment at higher values, but there was no clear “safe threshold” — just a steadily climbing hazard ratio as values rose from the mid-70s upward.
The biology of 70-85 mg/dL reflects a system in tight homeostatic control. In this range, insulin secretion is well matched to glucose output, the liver responds appropriately to insulin’s suppressive signal, and glycation is minimal — the non-enzymatic attachment of glucose to proteins that produces advanced glycation end-products (AGEs), tied to arterial stiffness, kidney damage, neuropathy. Glycation proceeds even at “normal” glucose levels. Just more slowly at lower values.
A fasting glucose of 87 mg/dL versus 97 mg/dL doesn’t sound like much. But glycation rate is roughly proportional to ambient glucose concentration. Someone averaging FBG of 90 mg/dL is glycating proteins and collagen meaningfully less over decades than someone at 97, even though both would be called “normal.” The cumulative glycation difference over 30 years between those two values is estimated to correspond to several years of physiological aging in vascular and neural tissue.
The Dawn Phenomenon: Why Morning Glucose Can Be Misleading
Kevin mentioned his fasting glucose varied considerably morning to morning — sometimes 92, sometimes 101, occasionally as high as 107 — even though he hadn’t changed what he was eating. He wondered if he was misreading his meter, or testing at different times. Neither. He was experiencing the dawn phenomenon.
The dawn phenomenon is a normal physiological process in which cortisol, growth hormone, and glucagon surge in the early morning hours (typically 3-8 AM) to prepare the body for waking. That hormonal surge stimulates hepatic glucose output — the liver releasing glucose to make sure the brain has adequate fuel for the transition from sleep to wakefulness. The result: a modest rise in blood glucose in the early morning, even with zero food intake, peaking around waking and subsiding over the first 1-2 hours of the day.
In metabolically healthy people, the dawn phenomenon produces a modest, well-controlled rise that clears quickly. In people with insulin resistance or impaired glucose metabolism, the liver’s response to the cortisol/glucagon surge is exaggerated, and insulin’s ability to suppress it is impaired — producing a larger, more prolonged fasting glucose elevation. Which is why some people with insulin resistance show their highest readings first thing in the morning, before any food at all.
Kevin’s variability (92 versus 107) likely reflected differences in cortisol on different mornings (stress, sleep quality, sleep duration all affect morning cortisol significantly), different testing times relative to waking (5 AM versus 8 AM can show meaningfully different values inside the dawn phenomenon window), and day-to-day variation in his liver’s insulin sensitivity based on the prior day’s exercise, food choices, and stress.
For accurate FBG tracking: standardize the conditions. Same time each morning, same number of hours after waking (immediately on waking is most consistent), before caffeine or exercise. Take 3-5 readings over a week and average them rather than trusting a single number. The average tells you more than any one data point.
HOMA-IR: A Better Insulin Resistance Marker Than FBG Alone
Fasting blood glucose alone is a fairly insensitive marker of insulin resistance in its early stages. Someone with significant insulin resistance may hold normal fasting glucose for years by compensating with massively elevated insulin secretion. The pancreatic beta cells work overtime, pumping out far more insulin than a metabolically healthy person would need, forcing glucose into resistant cells to keep the blood glucose reading “normal.” The problem is advancing. Insulin resistance is worsening. But the glucose number looks fine because the pancreas is quietly compensating for it.
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) fixes that blind spot by measuring fasting glucose AND fasting insulin together. The formula: HOMA-IR = (fasting glucose in mmol/L × fasting insulin in mIU/L) / 22.5. Or in mg/dL: HOMA-IR = (fasting glucose in mg/dL × fasting insulin in μIU/mL) / 405.
Reference values vary by study, but most functional medicine practitioners use: below 1.0 as optimal, 1.0-1.9 as borderline, 2.0+ as insulin resistant, 3.0+ as significantly insulin resistant. Conventional medicine typically flags HOMA-IR only above 2.5-3.0, which again reflects disease identification rather than optimization.
A 2012 study by Guerrero-Romero and Rodriguez-Moran found HOMA-IR predicted insulin resistance (confirmed by euglycemic insulin clamp — the gold standard) with 86.8% sensitivity and 80.9% specificity. For a simple, inexpensive blood test, that’s excellent diagnostic performance. Adding fasting insulin to a standard fasting glucose draw costs modestly more and delivers dramatically more information about where someone actually sits on the insulin resistance spectrum.
Kevin got his fasting insulin tested alongside his repeat glucose. Fasting glucose: 97 mg/dL. Fasting insulin: 14 μIU/mL. HOMA-IR: (97 × 14) / 405 = 3.35. By any clinical interpretation, significantly insulin resistant — despite the “normal” glucose. The glucose had been held at 97 by a pancreas working three times as hard as it should have needed to. The insulin number changed the whole picture.
HbA1c: The Three-Month Average and Its Limitations
Hemoglobin A1c (HbA1c or glycated hemoglobin) reflects average blood glucose over roughly the prior 3 months. Red blood cells live about 90-120 days, and glucose attaches non-enzymatically to hemoglobin within them at a rate proportional to ambient glucose concentration. The percentage of hemoglobin that’s been glycated is the HbA1c value.
Standard clinical reference ranges: below 5.7% normal, 5.7-6.4% prediabetes, 6.5%+ diabetes. Optimal for prevention is generally considered below 5.4%, with the lowest cardiovascular risk associated with values below 5.0% in most large cohorts.
HbA1c’s main value: it’s much harder to game than a single fasting glucose reading. One healthy dinner before a blood draw doesn’t move it meaningfully. It captures the cumulative glucose environment over months, making it more reliable than any single FBG reading.
Limitations: HbA1c is affected by red blood cell lifespan, which varies by individual and by certain conditions and nutrients. Iron deficiency anemia (extends RBC lifespan, artificially raises HbA1c), sickle cell disease, thalassemia (falsely lower it), and B12/folate deficiency all distort the reading. It also captures average glucose but misses variability — two people with identical HbA1c can have wildly different glucose excursion patterns, and evidence suggests glycemic variability (the amplitude of the swings) independently predicts vascular and metabolic outcomes beyond the average alone.
Kevin’s HbA1c was 5.6% — prediabetes range by functional standards, though conventional medicine would file it as high-normal. Combined with a HOMA-IR of 3.35, the picture was unambiguous: significant insulin resistance maintaining a borderline average glucose through compensatory hyperinsulinemia. The treatment priority wasn’t in question.
The Fasting Glucose Optimization Protocol
Based on the evidence, here’s the framework for moving fasting glucose from “normal but not optimal” toward the 70-85 mg/dL functional target.
Understand your complete metabolic picture first: Order fasting glucose, fasting insulin, HbA1c, and triglycerides in the same draw. Calculate HOMA-IR. If fasting insulin is above 8-10 μIU/mL with normal fasting glucose, that’s compensated insulin resistance — the most important stage to catch. Triglycerides/HDL ratio (TG÷HDL) above 2.0 is an independent marker of insulin resistance and elevated cardiovascular risk.
Reduce refined carbohydrate load: The fastest way to lower fasting glucose is to reduce the glucose substrate fueling the problem. Cutting ultra-processed foods, sweetened beverages, and refined grains (white bread, white rice, crackers, cereal) typically produces measurable fasting glucose reductions within 2-4 weeks. Not about eliminating all carbohydrates — about eliminating the forms that produce the largest, fastest glucose excursions.
Strategic exercise timing: A 30-minute walk after the largest carbohydrate-containing meal of the day reduces postprandial glucose by 20-30% compared to sitting. Evening exercise (weight training or brisk walking) significantly reduces next morning’s fasting glucose by depleting muscle glycogen and increasing overnight glucose uptake. Consistent resistance training builds the insulin-sensitive muscle mass that dramatically improves whole-body glucose disposal over time.
Address the dawn phenomenon specifically: If the highest readings are in the morning, the intervention is evening carbohydrate management (less high-carb, high-GI food at dinner), better sleep quality and duration, and reduced evening cortisol elevation (no screens, no intense work in the 2 hours before bed). Dawn phenomenon amplitude correlates strongly with cortisol rhythm quality — people with dysregulated cortisol get exaggerated dawn glucose rises.
Consider targeted supplementation: berberine, taken with meals, is the most evidence-backed natural intervention for improving insulin sensitivity and lowering fasting glucose. Magnesium glycinate at night addresses the roughly 50% deficiency prevalence that independently impairs insulin receptor function. Chromium picolinate has consistent but modest evidence behind it. Ceylon cinnamon carries RCT evidence for an 18-29% fasting glucose reduction in diabetic subjects.
Monitor meaningfully: Test under identical conditions (same time, same fasted duration) 3-5 times weekly. Track the 7-day and 30-day rolling average, not individual readings. The trend over weeks matters more than any single data point. Recheck fasting insulin and HbA1c at 3-month intervals to see whether insulin resistance is improving (HOMA-IR declining) before the glucose marker moves dramatically.
What Happened to Kevin
Kevin implemented the protocol systematically. Cut out the daily afternoon candy bar and sweetened coffee drinks — that alone was substantial. Started a walking program, 30 minutes after dinner, seven days a week. Added two resistance training sessions weekly. At month three, a complete metabolic recheck.
Fasting glucose: 84 mg/dL. Fasting insulin had dropped from 14 to 7.2 μIU/mL. HOMA-IR fell from 3.35 to 1.55. HbA1c: 5.2%. He’d moved from significantly insulin resistant to marginally above optimal in 90 days. No medications.
His doctor looked at the results and said “great, keep doing what you’re doing.” No discussion of what specifically he’d done or why it worked. That’s the tragedy of the 12-minute annual physical model — the right changes happened, the markers improved, and there’s no system for understanding why, capturing the protocol, or applying it to the next patient in the same situation.
Kevin’s situation wasn’t unique. It’s a template. A large fraction of the 96 million American adults with prediabetes could follow the same trajectory — catch it early through meaningful testing, understand what the numbers actually mean, implement targeted interventions, and get to the optimal range before the disease progresses. The conventional threshold sits at 100 mg/dL for a reason: it identifies people already significantly impaired. An optimal health approach starts the conversation at 85.
Common Questions About Fasting Blood Sugar
Q: My fasting glucose is 92 and my doctor says it’s fine. Should I be worried?
Not worried. Paying attention. A fasting glucose of 92 is within the normal clinical range but above the functional optimal range of 70-85. The evidence suggests meaningfully elevated cardiovascular risk compared to values in the 70s-low 80s, and it indicates metabolic regulation that isn’t at peak efficiency. Worth testing fasting insulin and HbA1c to understand whether this represents compensated insulin resistance. If insulin is elevated (above 8-10), the appropriate response is intervention to improve insulin sensitivity. If insulin is low-normal with FBG in the low 90s, less urgent, but still worth monitoring and improving.
Q: What fasting glucose indicates true metabolic health?
The functional target is 70-85 mg/dL, most evidence pointing to values below 85 as optimal. Below 70 warrants investigation — can indicate hypoglycemia susceptibility or inadequate carbohydrate intake. The sweet spot is roughly 75-85 mg/dL on consistently measured fasting values, with fasting insulin below 5-8 μIU/mL and HOMA-IR below 1.0.
Q: Can ketogenic or low-carb diets artificially create “physiological insulin resistance”?
Yes — and this one is worth understanding. People on very low carbohydrate diets sometimes show elevated fasting glucose (85-100 mg/dL) and impaired glucose tolerance on an oral glucose tolerance test (OGTT), even while metabolically healthy. Mechanism: without regular carbohydrate exposure, muscles downregulate GLUT4 transporters and become less immediately responsive to insulin. Called “adaptive glucose sparing” or “physiological insulin resistance” — muscle reserves glucose for the brain since the body is fat-adapted. Metabolically benign. The marker to check in this scenario is fasting insulin — it’ll be very low, often below 5, distinguishing fat-adapted physiology from true insulin resistance, where fasting insulin runs high.
Q: Does stress affect fasting blood glucose?
Significantly. Cortisol is a counter-regulatory hormone that raises blood glucose through multiple mechanisms — stimulating hepatic gluconeogenesis, reducing insulin sensitivity in peripheral tissues, amplifying the dawn phenomenon. Chronically elevated cortisol from psychological stress, poor sleep, or overtraining can raise fasting glucose by 10-20 mg/dL independent of diet. One reason people going through highly stressful periods sometimes see their metabolic markers worsen with no dietary changes at all. Addressing the cortisol source — stress management, sleep optimization, training volume management — is a necessary part of glucose optimization for anyone with dysregulated cortisol.
Q: Is a CGM (continuous glucose monitor) worth using for someone without diabetes?
For 2-4 weeks of educational use, absolutely. A CGM reveals individual postprandial glucose responses to specific foods, shows how exercise timing affects glucose patterns, makes the dawn phenomenon visible, and identifies foods that spike glucose unexpectedly. Far more actionable than general dietary advice. The Zeevi 2015 Weizmann Institute study showed individuals vary dramatically in glucose response to identical foods — the same white bread that spikes one person to 180 mg/dL might barely register in another, due to microbiome differences. A CGM maps the personal response, not the average one. After the learning period, ongoing monitoring is optional — most people extract the key learnings within 2-4 weeks.
Q: How quickly can fasting glucose improve with diet and lifestyle changes?
Faster than most people expect. The liver’s response to improved insulin sensitivity can begin within days of dietary intervention. A study by Ludwig et al. found measurable fasting glucose improvements within 7-10 days of switching from high-glycemic to lower-glycemic eating in subjects with metabolic syndrome. Exercise-induced improvements in insulin sensitivity are detectable within 24-48 hours of a single session. For meaningful, sustained improvement — reaching the optimal range and holding it — most people need 8-12 weeks of consistent implementation. Kevin hit his target in 90 days. For more advanced insulin resistance, the timeline runs longer, but the direction of change is usually evident within 30 days of serious effort.
The Glycation Story: Why Glucose Range Matters Beyond Diabetes
The deeper reason to care about fasting glucose optimization — even inside the “normal” clinical range — is glycation. The process by which glucose molecules attach non-enzymatically to proteins, lipids, and DNA, producing advanced glycation end-products (AGEs) that accumulate in tissue over time and drive the pathological changes tied to accelerated aging and disease.
HbA1c is the most familiar clinical example of glycation — it measures the percentage of hemoglobin that’s been glycated, which is why it reflects average glucose exposure. But glycation doesn’t stop at hemoglobin. It happens in collagen (arterial stiffness, skin aging, wrinkle formation), lens proteins (cataracts), myelin sheaths (neuropathy), kidney filtration membranes (nephropathy), and endothelial cells lining blood vessels (atherosclerosis initiation).
The rate of glycation is roughly proportional to ambient glucose concentration. At 70 mg/dL average glucose, it proceeds slowly. At 95 mg/dL — still “normal” — meaningfully faster. At 130 mg/dL (early uncontrolled diabetes), fast enough that tissue damage accumulates into clinical disease within years. The difference between 75 and 95 mg/dL average glucose, compounded over 30 years of adult life, represents a significant difference in total AGE accumulation across collagen, arteries, and neural tissue.
This is why metabolic researchers describe poorly controlled blood sugar as “accelerated aging.” Not a metaphor — a description of the chemical process. AGEs accumulating in arterial walls create cross-links in collagen that stiffen arteries, directly elevating systolic blood pressure. AGEs in kidney filtration membranes increase glomerular leakiness, eventually measured as microalbuminuria. AGEs in lens proteins eventually cloud into cataracts. All glucose-driven aging processes, all beginning at glucose levels most doctors call normal.
The practical implication: keeping fasting glucose in the 70-85 range isn’t just diabetes prevention. It’s an aging-rate reduction strategy. Every point of average glucose reduction within the “normal” range translates to slower glycation damage accumulating in every tissue in the body. That’s the case a 45-year-old like Kevin needs to make to himself for why these interventions are worth the sustained effort even when his doctor says his numbers are fine.
The Insulin Resistance Timeline: When FBG Actually Moves
Understanding the timeline of insulin resistance progression explains why waiting for fasting glucose to flag at 100 mg/dL is such a late intervention.
Insulin resistance typically develops over 10-20 years through progressive stages. In the earliest stage, peripheral insulin resistance develops — muscles become less responsive to insulin, requiring more of it for the same glucose uptake. The pancreas compensates by secreting more insulin, and fasting glucose stays normal. This stage can persist for a decade with completely normal fasting glucose readings the entire time.
In the second stage, the pancreas is secreting much more insulin than a metabolically healthy person would need, but compensation still holds glucose normal. Fasting insulin runs elevated (8-20 μIU/mL). HbA1c may sit in the 5.0-5.5% range. Fasting glucose is still below 100 mg/dL. Conventionally, everything looks fine. But HOMA-IR is already elevated, cardiovascular risk markers are worsening, and the metabolic system is under real strain from the chronic hyperinsulinemia itself.
In the third stage, compensatory hyperinsulinemia starts failing. The pancreas has been working overtime for years; beta cell function begins declining. Fasting glucose starts rising above 95, then above 100. HbA1c creeps above 5.7%. This is when conventional medicine starts paying attention — but the process has been running for a decade or more already. Beta cell damage at this stage is partly reversible with aggressive intervention, but substantially harder to reverse than catching it in Stage 1 or 2.
Kevin was probably in Stage 2 when the numbers came back. His HOMA-IR of 3.35 with borderline fasting glucose meant his pancreas was working very hard to maintain the appearance of normal glucose regulation. Without intervention, he’d likely have crossed the prediabetes threshold (FBG 100+) within 2-5 years and the diabetes threshold within 8-12. With intervention, he’s back at Stage 0. The difference between catching it in Stage 2 versus Stage 3 is enormous — both in ease of reversal and in the magnitude of cardiovascular risk accumulated during the undetected progression.
Interpreting Your Numbers: A Practical Reference
Here’s the practical reference framework for interpreting the main glucose and insulin markers — organized by what the numbers actually mean for optimization, not just disease identification.
Fasting Blood Glucose: Below 70 mg/dL — investigate (hypoglycemia, excessive fasting, inadequate carbohydrate). 70-85 mg/dL — optimal. 85-99 mg/dL — suboptimal; further investigation with fasting insulin recommended; lifestyle intervention warranted. 100-125 mg/dL — clinical prediabetes; significant insulin resistance; aggressive lifestyle intervention required; discuss pharmacological options with physician. Above 126 mg/dL on two separate occasions — diabetes; medical management needed.
Fasting Insulin: Below 5 μIU/mL — optimal (note: expected if on a very low carb diet). 5-10 μIU/mL — normal, no concern. 10-15 μIU/mL — mildly elevated; early compensatory hyperinsulinemia possible; lifestyle attention warranted. Above 15 μIU/mL — significant insulin resistance regardless of fasting glucose; intervention required.
HbA1c: Below 5.0% — optimal. 5.0-5.6% — normal, but upper end warrants attention. 5.7-6.4% — prediabetes; significant intervention warranted. Above 6.5% — diabetes by clinical definition.
Triglycerides/HDL Ratio: Below 1.5 — optimal (good insulin sensitivity). 1.5-2.5 — borderline. Above 2.5 — consistent with significant insulin resistance (insulin resistance raises TG through hepatic lipogenesis and lowers HDL through CETP activity). One of the most accessible and underused markers of insulin resistance available on a standard lipid panel.
Kevin’s initial panel: FBG 97, fasting insulin 14, HOMA-IR 3.35, HbA1c 5.6%, TG/HDL ratio 3.1. Every marker pointing the same direction. His 3-month follow-up: FBG 84, fasting insulin 7.2, HOMA-IR 1.55, HbA1c 5.2%, TG/HDL ratio 1.6. The system had genuinely recalibrated. Not just one number improving — convergent improvement across all of them, because every one reflects the same underlying biology moving in the right direction.
The most important thing anyone can do with their annual blood work isn’t just check whether they’re in the “normal” range. It’s understanding what the numbers actually mean about how the metabolic system is functioning, where they sit on the trajectory from optimal to disease, and what specific interventions the specific pattern calls for. Normal is a starting point for the conversation, not the end of it. Kevin’s 97 was “normal.” It was also a warning that his doctor didn’t know how to read.
Beyond Fasting Glucose: The Postprandial Story
Fasting glucose tells one important thing about metabolic health. But some researchers argue that postprandial (after-meal) glucose patterns matter at least as much for cardiovascular and metabolic risk — and fasting measurements alone capture them poorly.
A major study published in 2002 in the European Heart Journal by the DECODE study group analyzed glucose data from 25,000 participants across Europe and found that 2-hour postprandial glucose after an oral glucose tolerance test was a stronger predictor of cardiovascular mortality than fasting glucose — and predicted outcomes independently of fasting glucose in people with fasting values below 100 mg/dL. You can have a “normal” fasting glucose of 92 and a dramatically impaired postprandial response, and that impaired response carries its own independent cardiovascular risk.
This is where CGM data becomes especially valuable — it captures the postprandial patterns fasting measurements miss entirely. Someone with FBG of 92 might spike to 178 mg/dL after their typical breakfast, spend 2 hours above 140 mg/dL, then spike again to 165 after lunch — a total hyperglycemia exposure invisible in the fasting number. The glycation burden from that daily pattern is substantial, even while the doctor keeps saying the fasting glucose is normal.
The optimal postprandial glucose target: peak below 120 mg/dL (1-hour postprandial), return to baseline (within 10-15% of fasting value) by 2 hours after eating. Values above 140 mg/dL at 1 hour are associated with measurable increases in oxidative stress markers and endothelial dysfunction. Values above 180 mg/dL produce acute vascular damage even in a single exposure. Most people eating a standard Western diet regularly exceed 140 mg/dL postprandially without ever knowing it — the data is invisible without a CGM.
Kevin’s CGM data during the protocol showed his standard lunch — a chicken sandwich on whole wheat with chips — was spiking him to 162 mg/dL at 45 minutes postprandial. Swapping to the same chicken on a salad base with olive oil kept his postprandial peak below 118 mg/dL. The fasting glucose improvement he achieved was impressive. But the postprandial improvement — cutting his daily glucose exposure by eliminating the routine spikes into the 150-165 range — was arguably the more important change, and it happened faster. By week two of CGM use, he’d mapped his personal responses to his common meals and made targeted swaps that substantially cut his total daily glucose exposure. That knowledge, gained from two weeks of data, was permanent. He didn’t need to wear the device forever. He needed the insights it gave him, and now he has them for life.
The Practical Framework: Applying Fasting Blood Sugar Morning In Real Life
